Addition of Curcumin‐QingDai correlates with clinical benefit in pediatric ulcerative colitis and inflammatory bowel disease‐unclassified

OBJECTIVES: Composite remission remains hard to achieve for patients with inflammatory bowel disease (IBD). Recently, a novel herbal-based combination therapy, Curcumin-QingDai (CurQD), has shown promise in improving rates of clinical remission for adults with ulcerative colitis (UC), however, experience in children is lacking. Here we describe efficacy and safety of CurQD in a pediatric cohort diagnosed with UC/IBD-unclassified (IBD-U). METHODS: We performed a retrospective chart review of children with a diagnosis of UC or IBD-U beginning CurQD. Data collection included demographics, disease extent and severity, medication history, surgical history, biomarkers, endoscopic and histologic reports, and intestinal ultrasound. Clinical disease activity measured by the pediatric ulcerative colitis activity index (PUCAI) was recorded at baseline, Weeks 8-12 and Week 24. RESULTS: A total of 35 patients with UC/IBD-U treated with CurQD met inclusion criteria, 28.6% were female and 62.9% had a diagnosis of UC. The median age at start of intervention was 14.0 years. Twenty-two (62.9%) were bio-experienced. Clinical response and clinical remission rates were 65.5% and 63.6%, respectively, by Week 24. Significant changes in calprotectin, ESR, albumin and hemoglobin were noted pre/post intervention. Side effects to CurQD were uncommon (14.2%) and mild in all cases. CONCLUSIONS: As management options in the pediatric population are limited, adjunctive therapy is often a crucial consideration in achieving clinical response in children with IBD. Our data suggests that the addition of CurQD may offer a safe and effective option for children with UC/IBD-U when a primary agent has not resulted in a durable clinical remission.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Gastroenterology and Nutrition
Published
2026-11-17
DOI
https://doi.org/10.1002/jpn3.70683
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Addition of Curcumin‐QingDai correlates with clinical benefit in pediatric ulcerative colitis and inflammatory bowel disease‐unclassified

Jennifer A. Strople, Joseph Runde, Joshua D. Prozialeck, Jonathan Cordova et al.
6 links
Journal of Pediatric Gastroenterology and Nutrition
Inflammatory Bowel Disease
article

Addition of Curcumin‐QingDai correlates with clinical benefit in pediatric ulcerative colitis and inflammatory bowel disease‐unclassified

Jennifer A. Strople, Joseph Runde, Joshua D. Prozialeck, Jonathan Cordova, Jeffrey Brown, Jiafeng Li, Francesca Sadovi, Gomez Amanda
article en

Abstract

OBJECTIVES: Composite remission remains hard to achieve for patients with inflammatory bowel disease (IBD). Recently, a novel herbal-based combination therapy, Curcumin-QingDai (CurQD), has shown promise in improving rates of clinical remission for adults with ulcerative colitis (UC), however, experience in children is lacking. Here we describe efficacy and safety of CurQD in a pediatric cohort diagnosed with UC/IBD-unclassified (IBD-U). METHODS: We performed a retrospective chart review of children with a diagnosis of UC or IBD-U beginning CurQD. Data collection included demographics, disease extent and severity, medication history, surgical history, biomarkers, endoscopic and histologic reports, and intestinal ultrasound. Clinical disease activity measured by the pediatric ulcerative colitis activity index (PUCAI) was recorded at baseline, Weeks 8-12 and Week 24. RESULTS: A total of 35 patients with UC/IBD-U treated with CurQD met inclusion criteria, 28.6% were female and 62.9% had a diagnosis of UC. The median age at start of intervention was 14.0 years. Twenty-two (62.9%) were bio-experienced. Clinical response and clinical remission rates were 65.5% and 63.6%, respectively, by Week 24. Significant changes in calprotectin, ESR, albumin and hemoglobin were noted pre/post intervention. Side effects to CurQD were uncommon (14.2%) and mild in all cases. CONCLUSIONS: As management options in the pediatric population are limited, adjunctive therapy is often a crucial consideration in achieving clinical response in children with IBD. Our data suggests that the addition of CurQD may offer a safe and effective option for children with UC/IBD-U when a primary agent has not resulted in a durable clinical remission.

Journal of Pediatric Gastroenterology and Nutrition
Northwestern University (US), Lurie Children's Hospital (US), Northwestern Medicine (US)
General Motors Corporation
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon